Abstract
Since the discovery that the v-Src oncogene encoded a protein kinase in 1978,
kinases have become a targeted therapy strategy in oncology for the
pharmaceutical industry. The perfect date between Gleevec and Chronic Myeloid
Leukemia (CML) will be hard to achieve by other inhibitors currently in
development, because of CMLE strong link to a sole pathogenic event - the
Philadelphia chromosome. Thus, it is expected that multiple inhibitors may
have to be used together to effect higher cure rates in cancers with multiple
genetic abnormalities.
Scope of this report
Drugs according to protein kinase target; Dual or multiple kinase inhibitor
analysis Targets according to indication Competitive landscape assessment
Protein kinase inhibitors on market Thorough review of the seven largest
cancer indications in the field of protein kinase inhibitors
Research and analysis highlights
The number of protein kinase inhibitor (PKI) drugs has risen sharply, as the
number of targets. The fiercest competition in PKI drug development is found
in breast, lung, leukemia, prostate, and colorectal cancer. Several big pharma
companies are out hunting for promising technology and drugs to complement
their internal pipeline.
Key reasons to read this report
- Understand the clinical and strategic challenges to the commercialization
of protein kinase inhibitor treatments
- Assess opportunities and risks for the continued development of innovative
developmental treatments
- Adopt knowledge from this analysis to drive strategic planning decisions
in oncology drug developmentTable of Contents
View Cart
